Pencoed Business Park
Pencoed CF35 5HY
United Kingdom
44 20 3819 8400
https://www.reneuron.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 26
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D | Executive Chairman | 430k | N/D | 1954 |
Dr. John David Sinden B.A., BA, M.A., MA, Ph.D. | Co-Founder | 103k | N/D | 1951 |
Ms. Suzanne Hancock | Chief Operations Officer | N/D | N/D | N/D |
Dr. Randolph Corteling Ph.D. | Chief Scientific Officer | N/D | N/D | N/D |
Mr. Simon Dew | Chief Business Officer | N/D | N/D | N/D |
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
L'ISS Governance QualityScore di ReNeuron Group plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.